Informations générales
  • Catégorie de maladie Troubles mentaux et du comportement (BASEC)
  • État du recrutement recrutement en cours (BASEC/ICTRP)
  • Lieu de l’étude
    Zurich
    (BASEC)
  • Responsable de l'étude Professor Dr. med. Sebastian Olbrich sebastian.olbrich@pukzh.ch (BASEC)
  • Source(s) de données BASEC: Importé de 04.03.2026 ICTRP: N/A
  • Date de mise à jour 04.03.2026 10:45
HumRes67900 | SNCTP000006828 | BASEC2024-01005

Nitrous Oxide ("Laughing Gas") for the Treatment of Suicidal Thoughts

  • Catégorie de maladie Troubles mentaux et du comportement (BASEC)
  • État du recrutement recrutement en cours (BASEC/ICTRP)
  • Lieu de l’étude
    Zurich
    (BASEC)
  • Responsable de l'étude Professor Dr. med. Sebastian Olbrich sebastian.olbrich@pukzh.ch (BASEC)
  • Source(s) de données BASEC: Importé de 04.03.2026 ICTRP: N/A
  • Date de mise à jour 04.03.2026 10:45

Résumé de l'étude

The NITOS study investigates whether inhalation of nitrous oxide (N2O) can reduce suicidal thoughts. Inpatients at the Psychiatric University Hospital Zurich (PUK) who report relevant suicidal thoughts can participate in this double-blind study. They will receive inhalation on Day 1 and Day 8 for approximately 45 minutes each time. However, they will not know whether they are receiving a placebo (oxygen/air) or nitrous oxide (N2O with oxygen). All patients will receive N2O at least once during the two sessions. The severity of suicidality will be documented one day before and after inhalation, using both self-ratings and observer ratings. Additionally, blood samples, electrocardiograms (ECGs), and electroencephalograms (EEGs) will be conducted.

(BASEC)

Intervention étudiée

N2O treatment: Inhalation of nitrous oxide (N2O) for approximately 45 minutes at a concentration of 50%. The N2O will be slowly titrated to 50% over several minutes during the treatment. The N2O will be mixed with oxygen and inhaled through a (nasal) mask. After the N2O treatment, the study participant will receive pure oxygen for about 3 to 5 minutes. The control treatment lasts as long as the N2O treatment and consists of 50% oxygen with air. After the treatment, the study participant will also receive pure oxygen for about 3 to 5 minutes.

(BASEC)

Maladie en cours d'investigation

Mental and behavioral disorders associated with suicidal thoughts/suicidality

(BASEC)

Critères de participation
1) Inpatient psychiatric patients aged 18-65 years; 2) Ability to provide written informed consent after being informed; 3) Moderate to severe suicidal thoughts/suicidality, defined as a score ≥3 on the MADRS suicide item (Item #10) and a self-assessment on the Beck Scale for Suicidal Ideation (BSS) items #4 plus #5 with a score ≥ 2. (BASEC)

Critères d'exclusion
F00-F09: Organic, including symptomatic, mental disorders (lifetime diagnosis) F10-F19: Mental and behavioral disorders due to the use of psychoactive substances (see details in the protocol template) F20-F29: Schizophrenia, schizotypal, and delusional disorders (lifetime diagnosis) Non-medical (i.e., recreational) use of inhaled N2O in the last 12 months Previous intolerance or hypersensitivity to N2O Critical illness Severe heart disease Pregnancy or breastfeeding Pulmonary hypertension Chronic cobalamin or folate deficiency Treatment with ketamine/esketamine within the last 4 weeks Recent (within the last 4 weeks) or current use of benzodiazepines exceeding 5 mg of lorazepam or equivalent per day Electroconvulsive therapy (ECT) within the last 3 months (BASEC)

Lieu de l’étude

Zurich

(BASEC)

non disponible

Sponsor

Professor Dr. med. Sebastian Olbrich

(BASEC)

Contact pour plus d'informations sur l'étude

Personne de contact en Suisse

Professor Dr. med. Sebastian Olbrich

+41 58 384 26 37

sebastian.olbrich@pukzh.ch

Psychiatrische Universitätsklinik Zürich

(BASEC)

Informations scientifiques

non disponible

Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)

Commission cantonale de Zurich

(BASEC)

Date d'approbation du comité d'éthique

06.08.2024

(BASEC)


Identifiant de l'essai ICTRP
non disponible

Titre officiel (approuvé par le comité d'éthique)
Nitrous Oxide in the Treatment of Acute Suicidal Ideation (BASEC)

Titre académique
non disponible

Titre public
non disponible

Maladie en cours d'investigation
non disponible

Intervention étudiée
non disponible

Type d'essai
non disponible

Plan de l'étude
non disponible

Critères d'inclusion/exclusion
non disponible

non disponible

Critères d'évaluation principaux et secondaires
non disponible

non disponible

Date d'enregistrement
non disponible

Inclusion du premier participant
non disponible

Sponsors secondaires
non disponible

Contacts supplémentaires
non disponible

ID secondaires
non disponible

Résultats-Données individuelles des participants
non disponible

Informations complémentaires sur l'essai
non disponible

Résultats de l'essai

Résumé des résultats

non disponible

Lien vers les résultats dans le registre primaire

non disponible